Brought to you by 
Intercell licenses VaccGen's encephalitis vaccine candidate
02 Jul 2003
Executive Summary
Development-stage pharmaceutical company VaccGen International has licensed Intercell AG (vaccines against infectious diseases and cancer) exclusive worldwide development and marketing rights (excluding Korea and the Caribbean) to its vaccine candidate against Japanese encephalitis virus (JEV).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intercell licenses VaccGen's encephalitis vaccine candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice